Vitamin B or L-arginine supplementation in hyperhomocysteinaemia: Think twice!

Cardiovascular Research

Volumn 96, Issue 2, 2012, Pages 165-166

  Balligand, Jean Luc ^a,b  

^a Pole of Pharmacology and Therapeutics (FATH)   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; PLACEBO; PROSTAGLANDIN F2 ALPHA; PYRIDOXINE; TETRAHYDROBIOPTERIN; VITAMIN B GROUP;

AMINO ACID BLOOD LEVEL; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG EFFICACY; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HYPERHOMOCYSTEINEMIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN URINE LEVEL; VASCULAR ENDOTHELIUM; VITAMIN SUPPLEMENTATION;

ARGININE; ARTERIAL OCCLUSIVE DISEASES; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; VITAMINS;

EID: 84867703040     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs233     Document Type: Editorial

References (15)

1. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324: 1149-1155.
2. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-2022.
3. Sydow K, Schwedhelm E, Arakawa N, Bode-Boger SM, Tsikas D, Hornig B et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst (e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 2003;57: 244-252.
4. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999;19:217-246.
5. Hart JL. Role of sulfur-containing gaseous substances in the cardiovascular system. Front Biosci (Elite Ed) 2011;3:736-749.
6. Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 2001;100:161-167.
7. Ebbing M, Bonaa KH, Nygard O, Arnesen E, Ueland PM, Nordrehaug JE et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 2009; 302:2119-2126.
8. Cunnington C, Van AT, Shirodaria C, Kylintireas I, Lindsay AC, Lee JM et al. Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation 2012;125:1356-1366.
9. Boger RH, Bode-Boger SM, Mugge A, Kienke S, Brandes R, Dwenger A et al. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 1995; 117:273-284.
10. Ohta F, Takagi T, Sato H, Ignarro LJ. Low-dose L-arginine administration increases microperfusion of hindlimb muscle without affecting blood pressure in rats. Proc Natl Acad Sci USA 2007;104:1407-1411.
11. Wilson AM, Harada R, Nair N, Balasubramanian N, Cooke JP. L-Arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 2007; 116:188-195.
12. Druhan LJ, Forbes SP, Pope AJ, Chen CA, Zweier JL, Cardounel AJ. Regulation of eNOS-derived superoxide by endogenous methylarginines. Biochemistry 2008;47: 7256-7263.
13. Buga GM, Singh R, Pervin S, Rogers NE, Schmitz DA, Jenkinson CP et al. Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production. Am J Physiol 1996;271:H1988-H1998.
14. Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA et al. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010;468:1115-1118.
15. Balligand JL, Feron O, Dessy C. eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissues. Physiol Rev 2009;89:481-534.